Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • SortNewest  |  Oldest  |  Most Replied Expand all replies
    • big there are so many tumour types that vis could be used for. decisions to initiate trials for other cancers would involve considering the tons of competition who have many different targets and the length of time to get from ind to approval. gen/roche have already looked a some of the other possible indications and started a few new trials in the last 6 months. it will be interesting to see if they add any more. i have disagreed with people on this board who say there is no downside for this company/stock, but long-term i think this is a great hold even amid this tremendous volatility. it has also been great for short term trading. i expect decent results, and subsequent approval, from the phiii gem/abraxane pancreatic trial, the results of which will probably be reported in september, in my opinion. so, as i have stated so many times, the first test (after vis for bbc) is for the triple gem/abraxane/vis for pancreatic, which i hope will be presented at the su2c show and show better results than the gem/abraxane alone - keeping in mind that our trial is a phii.

 
CRIS
2.47-0.03(-1.20%)Sep 29 4:00 PMEDT